Tuan Vu

Tuan Vu

Auto-generated profile, based on publicly available information

Tuan Vu

Department of Neurology University of South Florida Morsani College of Medicine Tampa Florida USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
RARohit Aggarwal
Rohit Aggarwal
CCChristina Charles-Schoeman
Christina Charles-Schoeman
JSJoachim Schessl
Joachim Schessl
ZBZsuzsanna Bata-Csörgő
Zsuzsanna Bata-Csörgő
MDMazen M. Dimachkie
Mazen M. Dimachkie
TLTodd Levine
Todd Levine
Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated.

27 April 2023 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
AMAndreas Meisel
Andreas Meisel
DAdjillali Annane
djillali Annane
TVTuan Vu
Tuan Vu
Renato MantegazzaRenato Mantegazza
Renato Mantegazza
MKMasahisa Katsuno
Masahisa Katsuno
TGthe CHAMPION MG Study Group
the CHAMPION MG Study Group
Introduction: Ravulizumab demonstrated efficacy and an acceptable safety profile versus placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. We report an interim analysis of the ongoing open-label extension (OLE) designed to evaluate long-term treatment effects. Methods: Following completion of the 26-week RCP, patients could enter the OLE; patients who received ravulizumab in the RCP continued the drug; patients who previously received placebo switched to ravulizumab. Patients receive body-weight-based maintenance dosing of ravulizumab every 8 weeks. Efficacy endpoints up to 60 weeks included Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores, with least-squares (LS) mean change and 95% confidence intervals (95% CI) reported. Results: Long-term efficacy and safety in the OLE were analyzed in 161 and 169 patients, respectively. Improvements in all scores were maintained through 60 weeks in patients who received ravulizumab during the RCP; LS mean change from RCP baseline in MG-ADL score was − 4.0 (95% CI: − 4.8, − 3.1; p < 0.0001). Rapid (within 2 weeks) and sustained improvements occurred in patients previously receiving placebo; LS mean change in MG-ADL score from OLE baseline to Week 60 was − 1.7 (95% CI: − 2.7, − 0.8; p = 0.0007). Similar trends were seen in QMG scores. Ravulizumab treatment was associated with a decreased rate of clinical deterioration events compared with placebo. Ravulizumab was well tolerated; no meningococcal infections were reported. Conclusion: Findings support the sustained efficacy and long-term safety of ravulizumab, administered every 8 weeks, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. ClinicalTrials.gov identifier: NCT03920293; EudraCT: 2018-003243-39.

1 June 2020 in Muscle & Nerve
Verified
Journal Article
Open access
PDF file
MRMichael H Rivner
Michael H Rivner
BQBrandy M Quarles
Brandy M Quarles
JPJin-Xiu Pan
Jin-Xiu Pan
ZYZheng Yu
Zheng Yu
JHJames F Howard
James F Howard
MLMei Lin
Mei Lin
Introduction: Our aim in this study was to identify the prevalence and clinical characteristics of LRP4/agrin‐antibody–positive double‐seronegative myasthenia gravis (DNMG).Methods: DNMG patients at 16 sites in the United States were tested for LRP4 and agrin antibodies, and the clinical data were collected.Results: Of 181 DNMG patients, 27 (14.9%) were positive for either low‐density lipoprotein receptor–related protein 4 (LRP4) or agrin antibodies. Twenty‐three DNMG patients (12.7%) were positive for both antibodies. More antibody‐positive patients presented with generalized symptoms (69%) compared with antibody‐negative patients (43%) (P ≤ .02). Antibody‐positive patients’ maximum classification on the Myasthenia Gravis Foundation of America (MGFA) scale was significantly higher than that for antibody‐negative patients (P ≤ .005). Seventy percent of antibody‐positive patients were classified as MGFA class III, IV, or V compared with 39% of antibody‐negative patients. Most LRP4‐ and agrin‐antibody–positive patients (24 of 27, 89%) developed generalized myathenia gravis (MG), but with standard MG treatment 81.5% (22 of 27) improved to MGFA class I or II during a mean follow‐up of 11 years.Discussion: Antibody‐positive patients had more severe clinical disease than antibody‐negative patients. Most DNMG patients responded to standard therapy regardless of antibody status.

16 April 2025 in European Journal of Neurology
Verified
Journal Article
Open access
TVTuan H. Vu
Tuan H. Vu
RMRenato Mantegazza
Renato Mantegazza
DADjillali Annane
Djillali Annane
MKMasahisa Katsuno
Masahisa Katsuno
AMAndreas Meisel
Andreas Meisel
TGthe CHAMPION MG Study Group
the CHAMPION MG Study Group
Background: Ravulizumab, an anti‐complement C5 monoclonal antibody, was efficacious with acceptable safety in the randomized controlled period (RCP) and interim open‐label extension (OLE) periods of the CHAMPION MG phase 3 trial in adults with anti‐acetylcholine receptor antibody‐positive (AChR‐Ab+) generalized myasthenia gravis (gMG). Here, we report final results from the OLE.Methods: Patients who completed the 26‐week RCP could enter the OLE and receive ravulizumab for up to 4 years. Efficacy and safety were assessed throughout the OLE.Results: Among all ravulizumab‐treated patients (n = 169; median [range] ravulizumab treatment, 759.0 [14.0, 1265.0] days), 161 entered the OLE (ravulizumab‐ravulizumab: n = 78; placebo‐ravulizumab: n = 83). Sustained improvements were observed in Myasthenia Gravis Activities of Daily Living (MG‐ADL) total scores (ravulizumab‐ravulizumab, least squares mean [95% CI] change from RCP baseline at week 164: −4.0 [−5.3, −2.8]; p < 0.0001; placebo‐ravulizumab, change from OLE baseline after 138 weeks of treatment: −2.1 [−3.3, −0.9]; p = 0.0005). One hundred and forty‐one out of 160 (88.1%) patients achieved a ≥ 2‐point improvement in MG‐ADL total score, and 59/141 (41.8%) achieved a score of 0 or 1; once achieved, 32/59 (54.2%) sustained this status for > 50% of their remaining time in the study. Similar improvements were observed in Quantitative Myasthenia Gravis and Myasthenia Gravis Quality of Life‐15 revised scores, and Neurological Quality of Life Fatigue subscale scores. Clinical deterioration event rates were reduced in the OLE versus placebo in the RCP. Corticosteroid usage was reduced in the OLE. Ravulizumab was well tolerated; no meningococcal infections were reported.Conclusion: Ravulizumab demonstrated clinically meaningful and durable efficacy and safety in adults with AChR‐Ab+ gMG.

9 January 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
TVTuan Vu
Tuan Vu
HDHacer Durmus
Hacer Durmus
MRMichael Rivner
Michael Rivner
SSSheetal Shroff
Sheetal Shroff
TRThomas Ragole
Thomas Ragole
JHJames F. Howard
James F. Howard
Myasthenia gravis (MG) is driven by the secretion of autoantibodies from pathogenic B cell maturation antigen (BCMA)-expressing plasma cells. In this phase 2b randomized, controlled, double-blind trial, we evaluated Descartes-08, an autologous BCMA-directed mRNA chimeric antigen receptor T cell therapy, in patients with generalized MG (gMG). Patients (n = 26) were randomly allocated to receive once-weekly intravenous infusions of Descartes-08 (n = 15) or placebo (n = 11) over 6 weeks. The primary endpoint was a ≥5-point improvement in the MG Composite (MGC) score at month 3. Secondary endpoints included the mean change from baseline in MGC, MG Activities of Daily Living (MG-ADL) and Quantitative MG (QMG) scores by month 12. At month 3, the proportion of patients achieving a ≥5-point improvement in the MGC score was significantly higher for those treated with Descartes-08 compared to placebo in the overall population (66.7% (n = 10/15) versus 27.3% (n = 3/11), P = 0.0472) and in a subpopulation of those positive for autoantibodies to the acetylcholine receptor (63.6% (n = 7/11) versus 12.5% (n = 1/8), P = 0.0258). For patients treated with Descartes-08, the changes from baseline in mean MGC, MG-ADL and QMG scores at month 4 were −7.1, −5.5 and −4.8, respectively, with 83.0% of patients achieving a sustained and clinically meaningful response at month 12. Notably, 33.0% of patients achieved minimum symptom expression (MSE) (MG-ADL score ≤1) by month 6, which was sustained through month 12. Among biologic-naive patients, 55.60% achieved MSE by month 6, which was maintained through month 12 without additional treatment. Descartes-08 was generally safe and well tolerated. Infusion-related reactions were the most common adverse events reported (Descartes-08, 80.0% (n = 16/20); placebo, 56.3% (n = 9/16)). In summary, a single course of six once-weekly infusions of Descartes-08 was well tolerated and resulted in sustained clinically meaningful responses among patients with gMG. ClinicalTrials.gov identifier: NCT04146051.

1 December 2023 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
TVTuan Vu
Tuan Vu
HWHeinz Wiendl
Heinz Wiendl
MKMasahisa Katsuno
Masahisa Katsuno
SRStephen W Reddel
Stephen W Reddel
JJJames F Howard Jr
James F Howard Jr
The terminal complement C5 inhibitor ravulizumab was engineered from the humanized monoclonal antibody eculizumab to have an extended half-life and duration of action. It binds to human terminal complement protein C5, inhibiting its cleavage into C5a and C5b, thus preventing the cascade of events that lead to architectural destruction of the postsynaptic neuromuscular junction membrane by the membrane attack complex, and consequent muscle weakness in patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). The 26-week randomized, placebo-controlled period (RCP) of the phase 3 CHAMPION MG study demonstrated the rapid efficacy of ravulizumab in reducing MG symptoms. Weight-based dosing of ravulizumab every 8 weeks provided sustained efficacy, in terms of patient-reported (Myasthenia Gravis–Activities of Daily Living) and clinician-reported (Quantitative Myasthenia Gravis) endpoints in patients with anti-AChR antibody-positive gMG. Pharmacokinetic and pharmacodynamic analyses showed therapeutic serum ravulizumab concentrations (> 175 μg/mL) were achieved immediately after the first dose and were maintained throughout 26 weeks, irrespective of patient body weight; inhibition of serum free C5 was immediate, complete (< 0.5 μg/mL), and sustained in all patients. Interim results from the open-label extension (OLE) showed that after 60 weeks, efficacy was maintained in patients continuing on ravulizumab. Rapid and sustained improvements in efficacy, similar to those seen in patients initiating ravulizumab in the RCP, were observed after initiation of ravulizumab treatment in patients who switched from placebo in the RCP to ravulizumab in the OLE. The findings from the RCP and OLE support ravulizumab’s favorable safety profile. In conclusion, ravulizumab has a simple weight-based administration and long dosing interval. Its targeted mechanism of action without generalized immunosuppression is reflected in its rapid onset of symptom improvement, sustained efficacy and good safety profile in the treatment of patients with anti-AChR antibody-positive gMG. Plain Language Summary: Ravulizumab in anti-AChR antibody-positive gMGRavulizumab was engineered from eculizumab to have an extended half-life and longer duration of action. It binds to terminal complement protein C5 to inhibit anti-AChR antibody-mediated activation of terminal complement and destruction of the neuromuscular junction.Pharmacokinetic/pharmacodynamic analyses support a simple weight-based administration and long dosing interval and show that therapeutic ravulizumab concentrations and complete inhibition of C5 were achieved immediately after the first dose.The 26-week randomized placebo-controlled period (RCP) of the CHAMPION MG study in patients with anti-AChR antibody-positive gMG showed that ravulizumab has rapid and sustained efficacy with good safety and tolerability across a broad range of patients.Ravulizumab’s efficacy, safety, and tolerability were confirmed in interim analyses of the open-label extension study (including data for up to 60 weeks from the RCP baseline): efficacy was maintained in patients remaining on ravulizumab; rapid and sustained efficacy was established in patients switching from placebo to ravulizumab.